The Biostatistics Shared Resource ofthe Cancer Center at UCD was established in November 2000, with substantial institutional support, and has facilitated research efforts of the Cancer Center through two funding cycles of the CCSG. The purpose of the Biostatistics Shared Resource is to provide Cancer Center investigators with analytic support for projects internally funded by the Cancer Center and with design support for proposals for externally funded research. The goals ofthe Shared Resource are to: provide statistical expertise for the design of new studies, including sample size and power calculations and analytic plans;provide statistical advice and carry out analyses for research funded within the Cancer Center Programs and other Shared Resources, including pilot studies and quantitative assessment of methodology;foster development of externally funded research on statistical methodology relevant to the research goals of the Cancer Center;provide statistical consultation to the Scientific Review Board and for data monitoring boards;and provide education and mentoring in the biostatistics skills necessary for cancer researchers. The Shared Resource has a strong record of accomplishment during this funding cycle. We have expanded the number of faculty members and staff, collaborated on the design and planning of virtually every new research project in the Cancer Center, co-authored papers in a wide range of cancer-related research, contributed new statistical methodology directly related to cancer, and played a key role in the administration of the Cancer Center. Every clinical protocol receives full statistical review and must have a named statistician. In addition, our faculty members have played an active role in the education mission ofthe Cancer Center, especially in mentoring fellows and junior faculty beginning their research careers in cancer, leading to successful publications and funding for a growing number of our mentees. Our growing role is reflected in the increasing demand for our services and in the success ofthe Center's research mission. Close to half of all biostatistical collaboration in the School of Medicine is cancer-related, reflecting our ability to leverage institutional and CTSA support and our commitment to provide high-quality statistical support.

Public Health Relevance

Biostatistical collaboration is essential for all aspects of cancer research to ensure careful design and analysis of studies. Our resource helps develop the understanding the great variation in cancer and using that understanding to improve treatment, prevention, and care. In addition, it mentors a new generation of cancer researchers.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Davis
United States
Zip Code
Semrad, Thomas; Barzi, Afsaneh; Lenz, Heinz-Josef et al. (2015) Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. Int J Clin Oncol 20:518-24
Brostoff, Terza; Dela Cruz Jr, Florante N; Church, Molly E et al. (2014) The raccoon polyomavirus genome and tumor antigen transcription are stable and abundant in neuroglial tumors. J Virol 88:12816-24
Kirschbaum, Mark H; Foon, Kenneth A; Frankel, Paul et al. (2014) A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma 55:2301-4
Mayadev, Jyoti; Qi, Lihong; Lentz, Susan et al. (2014) Implant time and process efficiency for CT-guided high-dose-rate brachytherapy for cervical cancer. Brachytherapy 13:233-9
Daly, Megan E; Beckett, Laurel A; Chen, Allen M (2014) Does early posttreatment surveillance imaging affect subsequent management following stereotactic body radiation therapy for early-stage non-small cell lung cancer? Pract Radiat Oncol 4:240-6
Li, Tianhong; Maus, Martin K H; Desai, Sonal J et al. (2014) Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. J Thorac Oncol 9:18-25
Campbell, Mel; Kim, Kevin Y; Chang, Pei-Ching et al. (2014) A lytic viral long noncoding RNA modulates the function of a latent protein. J Virol 88:1843-8
Li, Tianhong; Kung, Hsing-Jien; Mack, Philip C et al. (2013) Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 31:1039-49
Semrad, Thomas J; Eddings, Courtney; Dutia, Mrinal P et al. (2013) Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors. Anticancer Drugs 24:636-40
Maus, Martin K H; Mack, Philip C; Astrow, Stephanie H et al. (2013) Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy. J Thorac Oncol 8:582-6

Showing the most recent 10 out of 84 publications